Literature DB >> 15069991

Current national initiatives and policies to control drug costs in Europe: UK perspective.

Martin Duerden1, Narinder Gogna, Brian Godman, Kate Eden, Michael Mallinson, Nick Sullivan.   

Abstract

Healthcare represents a significant proportion of UK government expenditure leading to the introduction of a number of reforms to contain costs while improving the quality and efficiency of care. Equity is also a core principle. These objectives have led to the institution of a number of central initiatives including National Institute for Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), and the National Service Frameworks (NSFs). NICE has met with variable success, with a number of activities and measures proposed to enhance its contribution. Other measures recently instituted to improve quality and efficiency include risk sharing arrangements, prescribing incentive schemes coupled with academic detailing, and outcome guarantee schemes. Ongoing reforms will continue with an aging population and pressure on resources.

Mesh:

Year:  2004        PMID: 15069991     DOI: 10.1097/00004479-200404000-00009

Source DB:  PubMed          Journal:  J Ambul Care Manage        ISSN: 0148-9917


  4 in total

Review 1.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

2.  Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.

Authors:  Vicki C Tse; Wai Tong Ng; Victor Lee; Anne W M Lee; Daniel T T Chua; June Chau; Sarah M McGhee
Journal:  BMC Cancer       Date:  2011-07-09       Impact factor: 4.430

Review 3.  A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Authors:  Lianne Barnieh; Fiona Clement; Anthony Harris; Marja Blom; Cam Donaldson; Scott Klarenbach; Don Husereau; Diane Lorenzetti; Braden Manns
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

Review 4.  Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.

Authors:  Trevor Jozef Piatkiewicz; Janine Marie Traulsen; Tove Holm-Larsen
Journal:  Pharmacoecon Open       Date:  2018-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.